Juvmo (tavapadon) is an oral dopamine agonist indicated for the treatment of Parkinson’s disease in adults. Tavapadon is a selective partial agonist of dopamine D1 and D5 receptors, offering a differentiated mechanism from dopamine agonists that primarily target D2 and D3 receptors.
Juvmo can be used as monotherapy in patients with early Parkinson’s disease or in combination with levodopa in patients experiencing motor fluctuations.
Juvmo introduces a differentiated approach to Parkinson’s disease treatment through selective targeting of D1 and D5 dopamine receptors. Its oral administration provides an additional option for managing motor symptoms across different stages of the disease. By targeting dopamine signaling involved in motor control, Juvmo is designed to help improve motor function and daily activities in adults with Parkinson’s disease.
